Your browser doesn't support javascript.
loading
Effects of repetitive transcranial magnetic stimulation in children and young people with psychiatric disorders: a systematic review.
Gallop, Lucy; Westwood, Samuel J; Hemmings, Amelia; Lewis, Yael; Campbell, Iain C; Schmidt, Ulrike.
Affiliation
  • Gallop L; Centre for Research in Eating and Weight Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, PO Box 59, London, SE5 8AF, UK. lucy.gallop@kcl.ac.uk.
  • Westwood SJ; Department of Psychology, School of Social Science, University of Westminster, London, W1W 6UW, UK.
  • Hemmings A; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AB, UK.
  • Lewis Y; Centre for Research in Eating and Weight Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, PO Box 59, London, SE5 8AF, UK.
  • Campbell IC; Centre for Research in Eating and Weight Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, PO Box 59, London, SE5 8AF, UK.
  • Schmidt U; Hadarim Eating Disorder Unit, Shalvata Mental Health Centre, Hod Hasharon, Israel.
Article in En | MEDLINE | ID: mdl-38809301
ABSTRACT
Repetitive transcranial magnetic stimulation (rTMS) has demonstrated benefits in adults with psychiatric disorders, but its clinical utility in children and young people (CYP) is unclear. This PRISMA systematic review used published and ongoing studies to examine the effects of rTMS on disorder-specific symptoms, mood and neurocognition in CYP with psychiatric disorders. We searched Medline via PubMed, Embase, PsychINFO via OVID, and Clinicaltrials.gov up to July 2023. Eligible studies involved multiple-session (i.e., treatment) rTMS in CYP (≤ 25 years-old) with psychiatric disorders. Two independent raters assessed the eligibility of studies and extracted data using a custom-built form. Out of 78 eligible studies (participant N = 1389), the majority (k = 54; 69%) reported an improvement in at least one outcome measure of disorder-specific core symptoms. Some studies (k = 21) examined rTMS effects on mood or neurocognition, findings were largely positive. Overall, rTMS was well-tolerated with minimal side-effects. Of 17 ongoing or recently completed studies, many are sham-controlled RCTs with better blinding techniques and a larger estimated participant enrolment. Findings provide encouraging evidence for rTMS-related improvements in disorder-specific symptoms in CYP with different psychiatric disorders. However, in terms of both mood (for conditions other than depression) and neurocognitive outcomes, evidence is limited. Importantly, rTMS is well-tolerated and safe. Ongoing studies appear to be of improved methodological quality; however, future studies should broaden outcome measures to more comprehensively assess the effects of rTMS and develop guidance on dosage (i.e., treatment regimens).
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Child Adolesc Psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Child Adolesc Psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Affiliation country: United kingdom